# Evidence that cholinergic mechanisms contribute to hyperexcitability at early stages in Alzheimer’s disease

**Authors:** Helen E. Scharfman, Korey Kam, Áine M. Duffy, John J. LaFrancois, Paige Leary, Elissavet Chartampila, Stephen D. Ginsberg, Christos Panagiotis Lisgaras

PMC · DOI: 10.3389/frdem.2025.1513144 · 2025-06-17

## TL;DR

This paper suggests that early Alzheimer’s disease involves overactive brain cells, and cholinergic neurons may play a key role in this hyperactivity.

## Contribution

The paper introduces a novel hypothesis that cholinergic neurons are overly active early in Alzheimer’s disease, contributing to hyperexcitability.

## Key findings

- Mouse models show hyperexcitability occurs before plaque formation and memory loss.
- Inhibiting cholinergic receptors or neurons reduces hyperactivity in AD models.
- Maternal choline supplementation improves cognition and reduces pathology in AD models.

## Abstract

A long-standing theory for Alzheimer’s disease (AD) has been that deterioration of synapses and depressed neuronal activity is a major contributing factor. We review the increasing evidence, in humans and in mouse models, that show that there is often neuronal hyperactivity at early stages rather than decreased activity. We discuss studies in mouse models showing that hyperexcitability can occur long before plaque deposition and memory impairment. In mouse models, a generator of the hyperactivity appears to be the dentate gyrus. We present evidence, based on mouse models, that inhibition of muscarinic cholinergic receptors or medial septal cholinergic neurons can prevent hyperactivity. Therefore, we hypothesize the novel idea that cholinergic neurons are overly active early in the disease, not depressed. In particular we suggest the medial septal cholinergic neurons are overly active and contribute to hyperexcitability. We further hypothesize that the high activity of cholinergic neurons at early ages ultimately leads to their decline in function later in the disease. We review the effects of a prenatal diet that increases choline, the precursor to acetylcholine and modulator of many other functions. In mouse models of AD, maternal choline supplementation (MCS) reduces medial septal cholinergic pathology, amyloid accumulation and hyperexcitability, especially in the dentate gyrus, and improves cognition.

## Linked entities

- **Chemicals:** acetylcholine (PubChem CID 187), choline (PubChem CID 305)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** hyperactivity (MESH:D006948), depressed neuronal (MESH:D003866), neuronal hyperactivity (MESH:D001289), memory impairment (MESH:D008569), AD (MESH:D000544), amyloid (MESH:C000718787)
- **Chemicals:** acetylcholine (MESH:D000109), choline (MESH:D002794)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12209278/full.md

---
Source: https://tomesphere.com/paper/PMC12209278